Online Education Opportunities

FREE! Complete at your own pace, available online anytime! 

Register here: https://www.trainingmissinglogic.com/offers/oyMYNa6F/checkout

Take advantage of this unique masterclass series designed exclusively for healthcare leaders

What you'll get:

• Masterclass 1:  Finding Stability in a World of Crisis and Chaos 

•  Masterclass 2:  Becoming a Resilient Leader During Unprecedented Times 

•  Masterclass 3:  Living a Balanced Life Through the Hard Times and Beyond

Each masterclass comes with a workbook to guide your learning experience. 

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.

Register Here:
https://www.rockpointe.com/courses/nonmelanoma-skin-cancers-current-and-emerging-checkpoint-inhibitors-for-treating-advanced-basal-cell-and-squamous-cell-carcinomas/

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

FREE! Complete at your own pace, available online anytime! 

Register here: https://www.trainingmissinglogic.com/offers/oyMYNa6F/checkout

Take advantage of this unique masterclass series designed exclusively for healthcare leaders

What you'll get:

• Masterclass 1:  Finding Stability in a World of Crisis and Chaos 

•  Masterclass 2:  Becoming a Resilient Leader During Unprecedented Times 

•  Masterclass 3:  Living a Balanced Life Through the Hard Times and Beyond

Each masterclass comes with a workbook to guide your learning experience. 

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.

Register Here:
https://www.rockpointe.com/courses/nonmelanoma-skin-cancers-current-and-emerging-checkpoint-inhibitors-for-treating-advanced-basal-cell-and-squamous-cell-carcinomas/

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

FREE! Complete at your own pace, available online anytime! 

Register here: https://www.trainingmissinglogic.com/offers/oyMYNa6F/checkout

Take advantage of this unique masterclass series designed exclusively for healthcare leaders

What you'll get:

• Masterclass 1:  Finding Stability in a World of Crisis and Chaos 

•  Masterclass 2:  Becoming a Resilient Leader During Unprecedented Times 

•  Masterclass 3:  Living a Balanced Life Through the Hard Times and Beyond

Each masterclass comes with a workbook to guide your learning experience. 

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.

Register Here:
https://www.rockpointe.com/courses/nonmelanoma-skin-cancers-current-and-emerging-checkpoint-inhibitors-for-treating-advanced-basal-cell-and-squamous-cell-carcinomas/

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

FREE! Complete at your own pace, available online anytime! 

Register here: https://www.trainingmissinglogic.com/offers/oyMYNa6F/checkout

Take advantage of this unique masterclass series designed exclusively for healthcare leaders

What you'll get:

• Masterclass 1:  Finding Stability in a World of Crisis and Chaos 

•  Masterclass 2:  Becoming a Resilient Leader During Unprecedented Times 

•  Masterclass 3:  Living a Balanced Life Through the Hard Times and Beyond

Each masterclass comes with a workbook to guide your learning experience. 

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.

Register Here:
https://www.rockpointe.com/courses/nonmelanoma-skin-cancers-current-and-emerging-checkpoint-inhibitors-for-treating-advanced-basal-cell-and-squamous-cell-carcinomas/

FREE! Complete at your own pace, available online anytime! 

Register here: https://www.trainingmissinglogic.com/offers/oyMYNa6F/checkout

Take advantage of this unique masterclass series designed exclusively for healthcare leaders

What you'll get:

• Masterclass 1:  Finding Stability in a World of Crisis and Chaos 

•  Masterclass 2:  Becoming a Resilient Leader During Unprecedented Times 

•  Masterclass 3:  Living a Balanced Life Through the Hard Times and Beyond

Each masterclass comes with a workbook to guide your learning experience. 

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.

Register Here:
https://www.rockpointe.com/courses/nonmelanoma-skin-cancers-current-and-emerging-checkpoint-inhibitors-for-treating-advanced-basal-cell-and-squamous-cell-carcinomas/

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

FREE! Complete at your own pace, available online anytime! 

Register here: https://www.trainingmissinglogic.com/offers/oyMYNa6F/checkout

Take advantage of this unique masterclass series designed exclusively for healthcare leaders

What you'll get:

• Masterclass 1:  Finding Stability in a World of Crisis and Chaos 

•  Masterclass 2:  Becoming a Resilient Leader During Unprecedented Times 

•  Masterclass 3:  Living a Balanced Life Through the Hard Times and Beyond

Each masterclass comes with a workbook to guide your learning experience. 

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

This activity can be taken anytime.

Register here: https://www.rockpointe.com/courses/pustular-psoriasis-recognizing-and-treating-a-rare-but-serious-disease-2/

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

The AMA has a portal of opioid-related CME courses.

Click here to access the portal:
https://edhub.ama-assn.org/pages/opioid-cme-course

The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.

Register Here:
https://www.rockpointe.com/courses/nonmelanoma-skin-cancers-current-and-emerging-checkpoint-inhibitors-for-treating-advanced-basal-cell-and-squamous-cell-carcinomas/